Here are some sample widgets you could interact with from this dashboard:
(1) Revenues expected to be slightly ahead of consensus estimates
Trefis estimates BMY's Q3 2021 revenues to be $11.7 Bil, slightly ahead of the consensus estimate of $11.6 Bil
Estimated Revenues - 2021Q3(E)
Trefis Estimates for Bristol-Myers Squibb Revenues:
Expected Change (YoY): 10.8%
The chart to the right highlights trends in Bristol-Myers Squibb's Revenues over the last four quarters along with our forecast for Q3 2021.
Quarterly Revenue Trend
(2) EPS likely to marginally beat consensus estimates
BMY's Q3 2021 earnings per share (EPS) expected to be $1.96 per Trefis analysis, marginally beating the consensus estimate of $1.92 by 2.1%
Estimated EPS- 2021Q3(E)
Trefis Estimates for Bristol-Myers Squibb EPS:
Expected Change (YoY): 136.1%
The chart to the right highlights trends in BMY's EPS over the last four quarters along with our forecast for Q3 2021.
Quarterly EPS Trend
(3) Stock price estimate 50% higher than current market price
Trefis maintains a fair value of $86 for BMY's stock as opposed to the current market price of roughly $58.
BMY Stock Price
The Trefis Price Estimate for Bristol-Myers Squibb stock represents the fair value for the company's stock over a one-year horizon.
Details about the chances of a rise in BMY stock in the near term can be found in a separate interactive dashboard.
The chart to the right highlights trends in BMY's stock price at the end of each of the last four quarters as well as the current stock price.
Stock Price (Quarter End)
#1. Estimating Bristol-Myers Squibb's Total Revenues:
Bristol-Myers Squibb's Revenues have seen a substantial increase of 88.5% from around $23 Bil in FY2018 to $43 Bil in FY2020 and we expect it to increase to $47 Bil in FY2021
A Separate Interactive Dashboard Analysis On Bristol-Myers Squibb's Revenues Details How The Company Makes Money.
#2. Deriving Bristol-Myers Squibb's Adjusted Net Income:
Bristol-Myers Squibb's Adjusted Net Income has increased from around $6.5 Bil in FY2018 to $15 Bil in FY2020 and we expect it to increase to $17 Bil in FY2021
This change is likely to be led by higher revenues and improved margins.
A Separate Interactive Dashboard Analysis On Bristol-Myers Squibb's Margins Highlights The Company's Various Expenses Components In Detail.
Adjusted Net Income [AxB]
Adjusted Net Income Margin [A]
Total Revenue [B]
#3. Determining Bristol-Myers Squibb's Adjusted EPS:
Bristol-Myers Squibb's Adjusted EPS has increased from $3.98 in FY2018 to $6.44 in FY2020 and we expect it to increase to $7.56 in FY2021
The change in EPS can be attributed to an increase in adjusted net income and a lower expected share count due to stock repurchases.
Adjusted EPS [A÷B]
Adjusted Net Income [A]
Shares Outstanding [B]
#4. Estimating Bristol-Myers Squibb's Share Price:
Our Price Estimate of $86 For Bristol-Myers Squibb's Stock is based on our Detailed Valuation Model, and implies a 11.4x P/E Multiple on expected FY2021 Adjusted EPS of $7.56
Trefis Price Estimate [AxB]
Adjusted EPS [A]
P/E Multiple [B]